INBX vs SPCE · rev $1.3M vs rev $361.0K
Inhibrx Biosciences, Inc. (INBX) versus Virgin Galactic Holdings Inc (SPCE) — a side-by-side from cached financials, not a winner call.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Virgin Galactic Holdings Inc (SPCE) is a aerospace & defense company listed on NYSE.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
Latest reported SPCE revenue for 2026-06-30 was $361.0K. Net income was -$120.6M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. SPCE currently screens at market cap $388.0M.
INBX currently screens at market cap $1.28B. SPCE currently screens at market cap $388.0M.
Not investment advice. Open the INBX and SPCE stock pages for the full models.
Not investment advice.